Insiders SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-12 pm EDT			5-day change	1st Jan Change
1.45 ^USD	+2.11%		+2.84%	+36.79%

May. 19	Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	CI
May. 14	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SELLAS Life Sciences Group, Inc. Announces Executive Changes	Mar. 08	CI
Athersys Names Jane Wasman as Board Chair	23-10-02	MT
SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer	23-02-06	CI
SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality	23-01-05	CI
SELLAS Life Sciences Group, Inc. Announces Election of Katherine Bach Kalin to Its Board of Directors	22-08-16	CI
SELLAS Life Sciences Appoints Robert Francomano as CCO	22-03-14	MT
SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer	22-03-14	CI
SELLAS Life Sciences Group, Inc. Promotes John T. Burns to Senior Vice President, Finance and Chief Accounting Officer	22-01-05	CI
Sellas Life Sciences Group, Inc. Announces Executive Changes	21-02-04	CI
SELLAS Life Sciences Group, Inc. Establishes Independent Data Monitoring Committee of Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial	20-05-18	CI
SELLAS Life Sciences Group, Inc. Names Dragan Cicic, MD, as Senior Vice President, Clinical Development	20-02-10	CI
SELLAS Life Sciences Group, Inc. Announces Executive Changes	19-01-07	CI
SELLAS Life Sciences Group, Inc. Announces Management Appointments	18-12-18	CI
SELLAS Life Sciences Group, Inc. Announces Resignation of Fabio López from the Board of Directors, Effective July 27, 2018	18-07-23	CI
SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients; Appoints Jeffrey S. Weber as Chairman	18-06-01	CI
SELLAS Life Sciences Group, Inc Appoints Gregory M. Torre as Chief Regulatory Officer and Senior Vice President, Technical Operations Effective April 27, 2018	18-04-24	CI
SELLAS Life Sciences Group, Inc. Announces Executive Changes	18-04-20	CI
SELLAS Life Sciences Group Inc. Appoints Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary	18-03-21	CI
SELLAS Life Sciences Appoints Jane Wasman as Chair of Board of Directors	18-02-01	CI
SELLAS Life Science Group, Inc. to Appoint Angelos M. Stergiou as Chief Executive Officer	17-08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Insiders

Filters